BIOCANCELL THERAPEUTICS INC. 4
4 · BIOCANCELL THERAPEUTICS INC. · Filed Aug 7, 2012
Insider Transaction Report
Form 4
Clal Biotechnology Industries Ltd.
10% Owner
Transactions
- Conversion
Common stock
2012-07-31$0.22/sh+4,147,171$899,936→ 16,591,408 total - Purchase
Common stock
2012-07-31$0.22/sh+10,731,726$2,328,785→ 27,323,134 total - Conversion
Debenture
2012-07-31→ 0 totalExercise: $0.22From: 2008-07-30Exp: 2012-07-31→ Common stock
Footnotes (2)
- [F1]The 4,147,171 shares of Common Stock reported acquired herein are issuable to Clal Biotechnology Industries Ltd. ("CBI") as a result of the conversion of convertible debentures in a principal face amount of $800,000 (the "Debentures") at a conversion price per share of New Israeli Shekel ("NIS") 0.87. Such conversion price is due to adjustments of the initial conversion price of the Debentures, which was initially $0.716, in accordance with the terms of the Debenture. The conversion prices indicated in the table are based on the exchange rate of NIS and US dollar reported by the Bank of Israel on August 3, 2012 (NIS 4.007 for US$1.00).
- [F2]The 10,731,726 shares of Common Stock reported acquired herein were acquired through a private placement that was executed in NIS at a price of NIS 0.87 per share. The price indicated in the table is based on the exchange rate of NIS and US dollar reported by the Bank of Israel on August 3, 2012 (NIS 4.007 for US$1.00).